E-Mail
New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.
Published this week in the journal
Molecular Cancer Research, Cramer s study specifically looks at how the loss of two specific prostate tumor-suppressing genes MAP3K7 and CHD1 increases androgen receptor signaling and makes the patient more resistant to the anti-androgen therapy that is typically administered to reduce testosterone levels in prostate cancer patients. Doctors don t normally stratify patients based on this subtype and say, We re going to have to treat these people differently, but we think this should be considered before treating them with anti-androgen therapy because they appear to be already inherently resistant to the therapy, says Cramer, professor in the Department of Pharmacology. They re less likely to respond to the treatment.
Novel Genomic Alterations in Circulating Tumor Cells Tied to Castrate-Resistant Prostate Cancer
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Newly identified drugs can help treat oral and esophageal carcinomas
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Using cell culture and mouse model approaches, researchers from Tokyo Medical and Dental University (TMDU) have found a novel drug combination that can inhibit tumor growth in oral and esophageal carcinomas. They also identified a potential biomarker that can help predict patient sensitivity to this treatment. These findings provide valuable knowledge for the fight against these deadly cancers and demonstrate a potential new use for drugs currently approved for other diseases.